key: cord-0691373-4zqt300p authors: Guo, Caili; Sun, Xiaomin; Wang, Xiaowen; Guo, Qing; Chen, Dan title: Network Meta‐Analysis Comparing the Efficacy of Therapeutic Treatments for Bronchiolitis in Children date: 2017-11-03 journal: JPEN J Parenter Enteral Nutr DOI: 10.1002/jpen.1030 sha: ab9dafa8ec6532d6e45321b05db03bafae9d518b doc_id: 691373 cord_uid: 4zqt300p BACKGROUND: This study aims to compare placebo (PBO) and 7 therapeutic regimens—namely, bronchodilator agents (BAs), hypertonic saline (HS), BA ± HS, corticosteroids (CS), epinephrine (EP), EP ± CS, and EP ± HS—to determine the optimal bronchiolitis treatment. METHODS: We plotted networks using the curative outcome of several studies and specified the relations among the experiments by using mean difference, standardized mean difference, and corresponding 95% credible interval. The surface under the cumulative ranking curve (SUCRA) was used to separately rank each therapy on clinical severity score (CSS) and length of hospital stay (LHS). RESULTS: This network meta‐analysis included 40 articles from 1995 to 2016 concerning the treatment of bronchiolitis in children. All 7 therapeutic regimens displayed no significant difference to PBO with regard to CSS in our study. Among the 7 therapies, BA performed better than CS. As for LHS, EP and EP ± HS had an advantage over PBO. Moreover, EP and EP ± HS were also more efficient than BA. The SUCRA results showed that EP ± CS is most effective, and EP ± HS is second most effective with regard to CSS. With regard to LHS, EP ± HS ranked first, EP ± CS ranked second, and EP ranked third. CONCLUSIONS: We recommend EP ± CS and EP ± HS as the first choice for bronchiolitis treatment in children because of their outstanding performance with regard to CSS and LHS. Infants and children are most susceptible to bronchiolitis. 1 Almost 3 million people are infected with this disease every year, 2 and most cases occur in spring and autumn. Low to moderate fever, coughing, running nose, wheezing, and sneezing are the usual symptoms. Respiratory syncytial virus (RSV) causes 50%-80% of bronchiolitis cases and is believed to be its primary cause. 3 In recent years, scientists found out that other viruses such as human rhinoviruses (HRV), coronaviruses, and bocavirus may also cause bronchiolitis. 4 Therefore, it is of great importance to determine the optimal therapeutic regimen. Based on our investigation, most bronchiolitis regiments are controversial, and it is hard to draw a conclusive optimal treatment. Dexamethasone is considered efficacious because of significantly reduced hospitalization days and other clinical benefits. 5 However, there is also contradictory evidence. 6 One study proposed that 3% hypertonic saline (HS) ± epinephrine (EP) is more efficient than 0.9% normal saline ± EP in decreasing the length of hospitalization and other symptoms. 7 However, in another article, there was no significant discrepancy between the 2 treatments. 8 Through a 7-day observation, 1 study said EP ± dexamethasone lacked efficacy. 9 However, another article said this combination was effective and even performed better than bronchodilator agents (BAs) in reducing bronchiolitis attacks. 10 In reference to BA, salbutamol is also considered an effective BA for infants with mild bronchiolitis. However, not all agreed with this suggestion. 11 Moreover, the combination of HS and BA was more effective than normal saline ± BA in decreasing symptoms, 12 but no difference was found in the clinical bronchiolitis severity score (CBSS). 13 Researchers have proved that EP is more efficient and safer than salbutamol. 14 Another study supported EP's efficacy but could not reach a conclusion on which agent was safer. 15 It seems that EP is more reliable than salbutamol. Some scientists found that HS is better at reducing admission days than 0.9% normal saline. 16 However, another article suggested that the application of EP, HS, salbutamol, and normal saline showed no significant discrepancy in their efficacy in treating infants with mild bronchiolitis. 17 In summary, there is no consensus in current research; therefore, more trials and analysis are required. Several meta-analyses (MAs) have been conducted to assess the efficacy and toxicity of different therapeutic regimens. These analyzed most mainstream treatments, including BA, 18-20 HS, 21 corticosteroids (CS), 22 EP, 23 antibiotics, 24 and montelukast. 25 However, MAs are pairwise comparisons and cannot display a network of multiple therapies. Therefore, due to a lack of direct evidence, we have not been able to evaluate the superiority and inferiority of other therapies. A new research method should be introduced to solve this problem. Network meta-analysis (NMA) based on a Bayesian framework could compensate for the disadvantages of a traditional MA. NMA can make the best use of both direct and indirect evidence. In fact, this statistical approach has been applied for pharmaceutical selection and assessments more and more frequently. 24 This NMA aimed to compare the efficacy of 7 therapeutic regimens-BA, HS, CS, EP, BA ± HS, EP ± CS, and EP ± HS-and the placebo (PBO). We used the clinical severity score (CSS) and length of hospital stay (LHS) as the assessment criteria. In summary, this article synthesizes and ranks 8 interventions in terms of efficacy and finally proposes the optimal drug selection for the treatment of bronchiolitis in children. The Embase, PubMed, and China National Knowledge Internet (CNKI) databases were searched for related publications. The cutoff date was August 26, 2016, and there were not any language restrictions. Our searching strategy included the use of keywords and correlated expressions such as bronchiolitis, bronchodilator agents, hypertonic saline, epinephrine, corticosteroids, leukotriene inhibitors, antibacterial agents, and randomized controlled trial. To avoid missing any relative studies, we checked the cited reference list of each selected articles. Two reviewers did this parallel literature screening independently. There were 4 inclusion criteria: (1) patients were children who had a history of bronchiolitis or were diagnosed with bronchiolitis for at least 3 consecutive months, (2) study was a randomized controlled trial (RCT), (3) the study outcomes included CSS or LHS, and (4) there were enough relevant data concerning the outcomes. Two authors assessed the reports using the above selection criteria. If a study seemed to record a repeated patient sample, the report with the follow-up period most similar to the other included studies was selected. A third author resolved any disagreements that arose. Extracted characteristics of each report are displayed in Table 1 . This includes but is not limited to the name of conductor(s), publication year, country, CSS and the standard they used, sample size, age, treatments, route, RSV positive, and duration of symptoms. Furthermore, we listed the Jadad scale of included studies. All records had a score of 4 or higher. This indicates that the studies retrieved were normative and reliable. This study built a random-effects network based on a Bayesian framework using the Markov chain Monte Carlo methods. We plotted networks of the curative outcomes of several studies and specified the relation by mean difference (MD), standardized MD (SMD), and 95% credible interval (CI) across experiments to compare different bronchiolitis treatments. The surface under the cumulative ranking curve (SUCRA) was used to calculate the probability of the curative effect. It separately ranked each therapy on CSS and LHS. Scores ranged from 0 to 1, and a higher score indicated a greater efficacy. Statistical heterogeneity across the studies was assessed using heat plots and node-splitting plots. All computations were performed using the STATA 13.1 (StataCorp LP, College Station, TX) and R 3.3.1 (Lucent Technologies, Jasmine Hill, NJ) software. We screened out 2312 records using the search strategies previously described. A total of 1914 records remained after duplicates were removed, and 1874 articles were discarded due to unrelated treatment, comparison, or lack of quantitative outcomes. Forty articles were believed to have a high quality and valuable data. 5, 6, [8] [9] [10] [11] [13] [14] [15] [16] [17] Figure 1 shows the entire literature screening process. Table 1 displays all included studies. The results of the Jadad scale on included studies are shown in Supplementary Table S1 . Eight therapies, including the PBO, are synthesized into 1 network in Figure 2 . This NMA synthesized and made comparison among the PBO and 7 therapeutic regimens, including BA, HS, BA ± HS, CS, EP, EP ± CS, and EP ± HS ( When it comes to LHS, these 2 therapies had a better efficacy than the others. The same conclusion can also be drawn from the forest plots ( Figure 3 ). This NMA used both direct and indirect information; therefore, it was of great importance to assess the consistency of evidence collected. Node splitting ( Table 3 ) and heat plots (Supplementary Figure S1 ) were applied to check the consistency between direct and indirect evidence. According to Table 3 , there is a discrepancy between BA and HS (P = .025, less than the significance level of .05). The heat plots (Supplementary Figure S1) show no obvious inconsistency. In this study, 2 SUCRA plots (Figure 4 ) on the related outcomes were constructed. In relation to CSS, EP ± CS ranked first and EP ± HS ranked second. EP or BA ± HS also demonstrated a strong performance. Of the 7 therapies, HS performed the worst. With regard to LHS, all treatments were more efficient than PBO. Among them, EP ± HS was suggested to be the best therapeutic regimen. EP ± CS and EP ± HS showed a great curative effect both in CSS and LHS. EP ranked third after the 2 outcomes, and while BA ± HS was the strongest performer in terms of CSS, it scored poorly in LHS. In all, EP ± CS and EP ± HS proved to be the optimal treatments for bronchiolitis. EP also had a good curative effect. According to the symmetrical characteristics of the funnel plots, no obvious publication bias is observed (Supplementary Figure S2 ). According to SUCRA, EP ± CS ranks first in CSS and second in LHS, while EP ± CS take first place in LHS and second in CSS. This result exhibits that EP ± CS and EP ± HS have an outstanding performance with respect to efficacy. EP is a hormone and neurotransmitter, and it is also used as medication. 55 It originates from some neurons and paranephros. 55 EP can control blood glucose, pupil dilation, cardiac output, and blood flow by affecting α and β receptors. CS is a type of steroid hormone that is extracted from vertebrates' adrenal cortex or some synthetic analogues of hormones. CS is usually applied to physiologic processes such as protein catabolism, immune response, and so on. 56 It is a widely used intervention, and there are several kinds of HS concentrations, the most common being 3%. Three percent HS plays an important role in treating severe hyponatremia, acutely increased intracranial pressure, and critical care settings. 57 Inhalational HS is believed to have a curative effect on respiratory problems such as bronchiolitis. 58 Based on our research, a combination of these medicines showed a better efficacy than therapy with the use of 1 treatment alone. EP ± HS exhibited an outstanding curable effect in previous individual research and MAs. This research reveals that EP ± HS can successfully reduce LHS and CSS. This conclusion was confirmed by Miraglia Del Giudice et al, 7 who also demonstrated that 3% HS ± EP was able to decrease symptoms and LHS. A report that claimed that 3% HS ± EP could improve CSS in infants with mild to moderate viral bronchiolitis 28 also supports our conclusions. Some research also took into consideration the concentration of HS as this may have a significant effect on efficacy. For example, it was demonstrated that 5% HS ± EP and 3% HS ± EP had a better performance in improving CSS than 0.9% normal saline. However, 5% HS ± EP had a stronger potential to reduce clinical severity than 3% HS ± EP. 37 This reminded us of the importance of concentration and why we should pay more attention to it in clinical practice. EP ± CS also had a brilliant performance with respect to CSS and LHS. Through the investigation and study of infants with bronchiolitis treated in the emergency department, it was found that dexamethasone (a kind of CS) with EP may effectively reduce LHS. 9 In addition, another study of infants with acute bronchiolitis implied that EP ± CS (dexamethasone) was significantly different from BA. 10 This is consistent with our conclusions. However, some researches and MAs had contradicting evidence to our results. A study that focused on the inhalation of 7% HS ± EP for patients with moderate to severe acute bronchiolitis 8 implied that 7% HS ± EP did not appear to show any significant clinical decrease in CSS compared with 0.9% normal saline ± EP. Grewal et al 40 conducted a randomized trial of severe bronchiolitis in the emergency department and concluded that 3% HS ± EP does not significantly reduce CSS compared with normal saline. Similarly, another experiment also could not find any difference in infants with mild bronchiolitis. 17 The above studies did not accord with most published results, but we could not simply omit them. Furthermore, some controversy also exists in the effect of EP ± CS. An RCT showed that EP ± CS did not play a role in bronchiolitis management for first-time wheezing infants due to a lack of positive effect on CSS and LHS. 31 This result was not reflected in our SUCRA results, and the inconsistency may be caused by several reasons. First, this NMA synthesized experimental data of HS without the consideration of HS concentration. The curative effect may be sensitive to concentration. Second, there may be some inconsistency between direct and indirect evidence. Last but not least, this study built a random-effects network based on a Bayesian framework using the Markov chain Monte Carlo methods, but it did not have an unbiased estimator. 59 This may consequently affect the SUCRA values. In summary, this NMA synthesized 7 therapeutic regimens as well as the PBO and ranked them on curative effect on CSS and LHS. This NMA adopted >1 outcome to thoroughly assess the treatments and to make sure we had better understanding of these 7 interventions. Furthermore, this study takes into consideration a greater volume of data. This is the main advantage of an NMA over a traditional MA and individual trials. All research involved in this study included high-quality RCTs. Some limitations affect our NMA results. First, there is a large discrepancy in sample size among the 7 treatments. This may have a significant impact on the corresponding 95% CI. The group partition was also very broad and did not consider intervention dose, patient age, patient health status, and so on. These factors should be further addressed. To some extent, a subgroup NMA could make up for these issues. This study could also have possibly missed some key data due to the omission of unpublished research. This study did not take into consideration any adverse effects, and as safety is an important aspect in assessing treatment, future studies should consider toxicity files. EP ± CS and EP ± HS had outstanding efficacy performance in terms of CSS and LHS and should be the first choice of bronchiolitis treatment in children. However, this NMA did not analyze the adverse effects of these 2 combined therapies; therefore, further research is still required. C. Guo contributed to the conception/design of the research; and C. Guo and D. Chen drafted the manuscript. All authors contributed to the acquisition, analysis, or interpretation of the data; critically revised the manuscript; agree to be fully accountable for ensuring the integrity and accuracy of the work; and read and approved the final manuscript. Lower respiratory tract infections Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Bronchiolitis: recent evidence on diagnosis and management New respiratory viral infections Efficacy of oral dexamethasone in outpatients with acute bronchiolitis Single oral dose of dexamethasone in outpatients with bronchiolitis: a placebo controlled trial Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized infants with bronchiolitis 7% Hypertonic saline in acute bronchiolitis: a randomized controlled trial Epinephrine and dexamethasone in children with bronchiolitis Additive effects of dexamethasone in nebulized salbutamol or L-epinephrine treated infants with acute bronchiolitis Efficacy of bronchodilators in the treatment of bronchiolitis Stimulus/secretion coupling factors in glucose-stimulated insulin secretion: insights gained from a multidisciplinary approach The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline combination in moderate bronchiolitis Efficacy of nebulised epinephrine versus salbutamol in hospitalised children with bronchiolitis Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrinenormal saline, and 3% saline in mild bronchiolitis Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis Efficacy of bronchodilator therapy in bronchiolitis: a meta-analysis Hypertonic saline (HS) for acute bronchiolitis: systematic review and meta-analysis Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis Azithromycin for the treatment of obliterative bronchiolitis after hematopoietic stem cell transplantation: a systematic review and meta-analysis Systematic review of montelukast's efficacy for preventing post-bronchiolitis wheezing A randomized trial of nebulized 3% hypertonic saline with salbutamol in the treatment of acute bronchiolitis in hospitalized infants Therapeutic effects of ventolin versus hypertonic saline 3% for acute bronchiolitis in children Nebulised hypertonic saline (3%) among children with mild to moderately severe bronchiolitis-a double blind randomized controlled trial A comparative study on use of 3% saline versus 0.9% saline nebulization in children with bronchiolitis Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial Effect of combined dexamethasone therapy with nebulized r-epinephrine or salbutamol in infants with bronchiolitis: a randomized, double-blind, controlled trial Racemic adrenaline and inhalation strategies in acute bronchiolitis Tidal breathing responses to albuterol and normal saline in infants with viral bronchiolitis Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized infants with bronchiolitis Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants A randomized, controlled trial of nebulized terbutaline in the first acute bronchiolitis in infant less than 12 months old Management of bronchiolitis without antibiotics: a multicentre randomized control trial in Bangladesh A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis Computerized acoustic assessment of treatment efficacy of nebulized epinephrine and albuterol in RSV bronchiolitis Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience Comparison of the efficacy of nebulized L-epinephrine, salbutamol and normal saline in acute bronchiolitis: a randomized clinical trial Dexamethasone inhalations in RSV bronchiolitis: a double-blind, placebocontrolled study Tidal breathing flow-volume loops in bronchiolitis in infancy: the effect of albuterol Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing Salbutamol or mist in acute bronchiolitis Efficacy of corticosteroids in acute bronchiolitis: short-term and long-term follow-up Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis Controlled trial of nebulized salbutamol in children under 6 months of age with acute bronchiolitis Marks' basic medical biochemistry: a clinical approach (second edition) Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis A critical review of "a randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis Additional supporting information may be found online in the supporting information tab for this article.